Researchers from the US National Institutes of Health (NIH) and Marengo Therapeutics Inc. previously developed a first-in-class, bifunctional therapeutic molecule (STAR-0602) that selectively activates V β6 and V β10 T-cell receptor-expressing T cells and boosts antitumor responses in human ex vivo tumor models.